(Press-News.org) ATS 2012, SAN FRANCISCO – A tiny, resilient metal wire designed to gather and compress diseased lung tissue may offer relief to patients with severe heterogeneous emphysema, a subtype of the disease that involves specific, usually isolated areas of the lungs, according to the results of a multicenter international trial conducted in the Netherlands, Germany and France. The wire, called a lung volume reduction coil (LVRC), can be easily implanted and is designed to take the place of more invasive procedures used to improve the lung function of emphysema patients.
The study will be presented at the ATS 2012 International Conference in San Francisco.
"Our results indicate that LVRC treatment is technically feasible in both upper and lower regions of the lung in patients with severe heterogeneous emphysema, and results in significant improvements in pulmonary function, exercise capacity and quality of life, with an acceptable safety profile," said study lead author Dirk-Jan Slebos, MD, pulmonary physician at the University Medical Center Groningen (UMCG), The Netherlands.
Lung volume reduction is performed in patients with emphysema in an effort to isolate diseased lung tissue and allow healthy lung tissue to expand and function more efficiently, which in turn helps the patient to breathe and function better. Because heterogeneous emphysema involves different areas, or lobes, of the lung, surgery to contain diseased lung tissue can be complicated and extensive. Use of wire coils, which can be implanted in relatively noninvasive bronchoscopic procedures, is emerging as a more effective, and safer, option than surgery for these patients. Coils are compressed during implantation, and expand to their original shape once implanted in the lung tissue.
Although a previous single-center trial showed LVRC to be safe and effective in patients with severe upper-lobe emphysema, Dr. Slebos said this study involved patients treated at 11 different healthcare centers, and explored the safety, efficacy and feasibility of LVRC in both upper and lower lobes.
The study enrolled 53 patients who underwent 101 LVRC procedures, including 46 bilateral (both lungs) procedures and nine unilateral procedures. In each procedure, the clinicians implanted from eight to 14 coils, resulting in a study total of 1,070 coils being implanted. Safety was evaluated by recording all adverse events that occurred within the first 30 days following treatment, as well as those that occurred between 30 days and six months of treatment. Efficacy was measured by quality-of-life questionnaires, pulmonary function testing and exercise testing, all performed six months following treatment. Reported adverse events included exacerbation of chronic obstructive pulmonary disease (COPD), pneumonia, collapsed lung, chest pain and mild hemoptysis, or coughing up blood, which could be managed with standard care.
The researchers found that LVRC treatment resulted in significant improvement in respiratory measurements at six months, especially in patients whose lungs were severely hyperinflated. In this group, LVRC therapy resulted in significant improvements in lung function, hyperinflation, exercise capacity and quality of life measurements. In fact, severe hyperinflation at baseline appeared to be an indicator of better outcomes, Dr. Slebos noted.
"Hyperinflation of lung tissue is one of the key pathophysiological features of emphysema that is responsible for shortness of breath, and its magnitude seems to be a good indicator of successful LVRC treatment," he said.
Dr. Slebos said the trial is ongoing and continues to collect data.
"The results so far indicate that the LVRC is a safe and effective choice for treating patients with severe heterogeneous emphysema where current medical treatment fails, and as we continue to collect follow-up data, we hopefully will have a more complete profile of its applications in this patient population," he said.
###
"Lung Volume Reduction Coil Treatment For Patients With Severe Heterogeneous Emphysema, A Multicenter Feasibility Trial" (Session D15, Wednesday, May 23, 9:15 a.m., Room 2005-2007, Moscone Center; Abstract 27924)
* Please note that numbers in this release may differ slightly from those in the abstract. Many of these investigations are ongoing; the release represents the most up-to-date data available at press time.
Abstract 27924
Lung Volume Reduction Coil Treatment For Patients With Severe Heterogeneous Emphysema, A Multicenter Feasibility Trial
Type: Scientific Abstract
Category: 09.08 - COPD: Non - Pharmacological Treatment (CP)
Authors: D.-J. Slebos1, S. Blaas2, G. Deslee3, W. Geseirich4, F.J. Herth5, J. Hetzel6, M. Hetzel7, R. Kessler8, C.-H. Marquette9, M. Pfeifer2, F. Stanzel10, C. Witt11; 1University Medical Center Groningen - Groningen/NL, 2Klinikum Donaustauf - Donaustauf/DE, 3Hopital Maison Blanche CHU - Reims/FR, 4Asklepios - Gauting/DE, 5Thorax Klinik - Heidelberg/DE, 6UKT University Hospital - Tuebingen/DE, 7Krankenhaus vom Roten Kreutz - Stuttgart/DE, 8CHRU de Strasbourg - Strasbourg/FR, 9Hopital Pasteur, CHU Nice - Nice/FR, 10Lungenklinik - Hemer/DE, 11Charité - Universitätsmedizin Berlin - Berlin/DE
Abstract Body
Rationale:
The Lung Volume Reduction Coil (LVRC) is a bronchoscopic device made of self-expandable nitinol wire for the treatment of emphysema. A previous single center pilot study showed safety and efficacy in severe upper-lobe emphysema. In this study we investigated the feasibility, safety and efficacy of LVRC treatment in a multicenter cohort trial design in patients with severe upper or lower lobe heterogeneous emphysema.
Methods:
53 patients (29F/24M, 61.5yrs (±7.2)), FEV1 30.2%pred (±6.7%), RV 243%pred (±52%), RV/TLC 66.2 (±9.5), SGRQ 62.3 (±12.6) were bronchoscopically treated under general anesthesia using fluoroscopy with LVRCs (PneumRx, USA) in either one or two lungs (in two sequential procedures) in 11 European centers. Safety was evaluated by recording all adverse events (AEs), efficacy was measured by questionnaires, pulmonary function and exercise testing at 6 months post treatment. The trial is ongoing.
Results:
101 LVRC procedures were performed (46 bilateral, 9 unilateral). 40 patients were treated in the upper lobes and 13 in the lower lobes. A total of 1070 coils were placed with median 10 coils (range 8-14) placed per procedure in 48±24 min. Adverse events 30 days – 6months after the procedure were: COPD exacerbation (n=21), pneumonia (n=11), pneumothorax (n=3), chest pain (n=3), and mild hemoptysis (n=1). LVR-coil treatment resulted at 6 months in the overall group in a ΔFEV1 +13% (±4.9%), ΔRV -0.44L (±0.16), Δ6MWD +35m (±12) and ΔSGRQ -10 points (±2.3). RV%pred at baseline correlated significantly to improvement in RV after treatment (r2=0.453, p220%pred, the 6 months results are: ΔFEV1 +19% (±6.8%), ΔRV -0.57L (±0.21), Δ6MWD +42m (±14), and ΔSGRQ -14 points (±3.1).
Conclusion:
LVRC treatment is technically feasible in both upper and lower lobe severe heterogeneous emphysema and results in significant improvements in pulmonary function, exercise capacity and quality of life, with an acceptable safety profile. High RV at baseline seems to be an indicator of better outcome.
Funded by: PneumRx Inc, Mountain View, CA
Tiny implanted coil improves lung function in patients with severe emphysema
2012-05-23
ELSE PRESS RELEASES FROM THIS DATE:
Study shows antibiotic improves respiratory function in lung transplant patients
2012-05-23
ATS 2012, SAN FRANCISCO – Researchers in the United Kingdom have determined that azithromycin, a broad-spectrum antibiotic that also has anti-inflammatory properties, can be an effective treatment option for patients suffering from bronchiolitis obliterans syndrome (BOS), a life-threatening complication that occurs in the majority of patients following lung transplantation.
BOS is the leading cause of mortality after the first year following transplantation, and occurs in part when the body repeatedly rejects the transplanted lung tissue. The syndrome causes the airways ...
P. aeruginosa bacteria associated with increased hospitalizations in COPD patients
2012-05-23
ATS 2012, SAN FRANCISCO – Patients with chronic obstructive pulmonary disease (COPD) who become infected with the bacterium Pseudomonas aerguinosa are more likely to have worse clinical outcomes and experience more hospitalizations during the course of their disease than COPD patients who are not infected, according to researchers from Buffalo, N.Y.
The study will be presented at the ATS 2012 International Conference in San Francisco.
Bacterial bronchial infection plays a key role in the course of COPD, causing chronic inflammation as well as acute exacerbations of ...
Mortality rates decrease, chronic disease rates increase among HIV+ ICU patients
2012-05-23
ATS 2012, SAN FRANCISCO – The expanded use of antiretrovirals, potent drugs used to treat retroviral infections such as human immunodeficiency virus (HIV), has been linked to significant decreases in hospital mortality rates among severely ill HIV-positive(HIV+) patients nationwide, primarily due to a decrease in opportunistic infections, according to a new study by researchers at Stanford University. Despite these encouraging data, the study also revealed that in this population, chronic diseases and bloodstream infections are on the rise.
The study results will be presented ...
Breast MRI helps predict chemotherapy's effectiveness
2012-05-23
OAK BROOK, Ill. – Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online in the journal Radiology.
Women with breast cancer often undergo chemotherapy prior to surgery. Research has shown that women who receive this treatment, known as neoadjuvant chemotherapy, are more likely to achieve breast conservation than those receiving chemotherapy after surgery.
Clinicians track a patient's response to neoadjuvant ...
Researchers uncover new ways sleep-wake patterns are like clockwork
2012-05-23
Researchers at New York University and Albert Einstein College of Medicine of Yeshiva University have discovered new ways neurons work together to ease the transition between sleep and wakefulness. Their findings, which appear in the journal Neuron, provide additional insights into sleep-wake patterns and offer methods to explore what may disrupt them.
Their study explored the biological, or circadian, clocks of Drosophila fruit flies, which are commonly used for research in this area. This is because it is relatively easy to find mutants with malfunctioning biological ...
Mayo Clinic urologists present findings at American Urological Association Annual Meeting
2012-05-23
ROCHESTER, Minn. -- Mayo Clinic researchers will present findings on prostate cancer risk, screening, treatment and other urological research at the annual meeting of the American Urological Association May 19-23 in Atlanta. Mayo Clinic urologists will also be available to provide expert comment for reporters covering the conference.
Mayo Clinic studies that will be presented and their embargo dates include:
No negative impact on overall survival from post-prostate surgery hormone therapy
Embargoed until 10:30 a.m. ET Monday, May 21
In a first-of-its-kind study ...
Treating pain with transplants
2012-05-23
A new study finds that transplanting embryonic cells into adult mouse spinal cord can alleviate persistent pain. The research, published by Cell Press in the May 24th issue of the journal Neuron, suggests that reduced pain results from successful integration of the embryonic cells into the host spinal cord. The findings open avenues for clinical strategies aimed not just at treating the symptoms of chronic debilitating pain, but correcting the underlying disease pathology.
There are two major classes of chronic pain: inflammatory pain that results from injury to tissue, ...
Why cutting sugar can control seizures: Scientists identify metabolic regulator of epilepsy
2012-05-23
A new study unravels a link between a protein that can modify cellular metabolism in the brain and seizure susceptibility. The research, published by Cell Press in the May 24th issue of the journal Neuron, may lead to the development of new treatments for epilepsy.
Epilepsy is a disorder characterized by seizures, unpredictable and abnormal bursts of electrical activity in the brain. Some cases of epilepsy are resistant to traditional drug treatments but can be improved by a "ketogenic" diet. This type of diet, which is very low in sugars and high in fat, forces neurons ...
Dollars and sense: Why are some people morally against tax?
2012-05-23
As the U.S. presidential election campaigns heat up, the economic debate is dominated by bailouts, austerity and, inevitably, taxation. Now a new study published in Symbolic Interaction asks why tax is such an important issue to voters and explores the moral ideas which underpin their views.
Americans are famously hostile to taxes even though they are not heavily taxed in comparison to Canadians and the British. In their study Dr Jeff Kidder and Dr Isaac Martin, from Northern Illinois University and the University of California-San Diego, explore how middle class feelings ...
Socioeconomics may affect toddlers' exposure to flame retardants
2012-05-23
DURHAM, N.C. -- A Duke University-led study of North Carolina toddlers suggests that exposure to potentially toxic flame-retardant chemicals may be higher in nonwhite toddlers than in white toddlers.
The study also suggests that exposure to the chemicals is higher among toddlers whose fathers do not have a college degree, a proxy measure of lower socioeconomic background.
Hand-to-mouth activity may account for a significant amount of the children's exposure to the contaminants, according to the study, which appears Wednesday in the journal Environmental Health Perspectives. ...